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General introduction
       Airway hyperresponsiveness (AHR) and inflammation leading to an increased
airway resistance are characteristic features of bronchial asthma.') The importance of AHR
in the pathogenesis of asthma has been suggested by its correlation with the severity of this
disease.2) Therefore, the underlying mechanisms of AHR should be deterrnined for the
therapy of asthma.
       The inflammation of asthmatic lungs is characterized by infTiltration of eosinophils,
mast cells and lymphocytes to airvvay walls. Activation of these cells results in the release of
a plethora of inflammatory mediators that individually or in concert induce changes in the
airway wall geometry and produce the symptoms of the disease.
       It has been reported that airways of asthmatic patients are hyperresponsive both in
vivo and in vitro.3L5) For instance, airway smooth muscles obtained from hyperresponsive
patients have also in vitro hyperresponsiveness to methacholine.3) Likewise, our laboratory
has recently demonstrated both in vivo and in vitro AHR to acetylcholine (ACh) in rats that
were actively sensitized and repeatedly challenged with aerosolized antigen.6) In the rat
model of AHR, it was also demonstrated that muscarinic receptor density and antagonist
affTinity of airway smooth muscle were within normal level.') Moreover, no significant
difference in bronchial smooth muscle contraction induced by depolarization with high K'
was observed between the AHR and controi groups.8) Thus, it is possible that the
mechanisms responsible for the AHR exist, at least in part, in the downstream pathway of
muscarinic receptor signaling.
       Contraction of smooth muscle is initiated by a Ca2'-mediated change in the thick
filaments, whereas in striated muscle Ca2" mediates contraction by changes in the thin
filaments. In response to specific stimuli in smooth muscle, the intracellular concentration of
Ca2' increases, and this activator Ca2' combines with the acidic protein calmodulin. This
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complex activates myosin light chain (MLC) kinase to phosphorylate the light chain of
myosin. Cytosolic Ca2" is increased through Ca2' release from intracellular stores
(sarcoplasmic reticulum) as well as entry from the extracellular space through Ca 2' channels
(receptor-operated Ca2' channels).
      In various rypes of smooth muscle including airways9), agonist-induced Ca2'
sensitization of myofilaments at the contractile response has been demonstrated. The state
of myosin light chain phosphorylation is fumher regulated by MLC phosphatase.'O"8) There
are three subunits of MLC phosphatase: a 37-kD catalytic subunit, a 20-kDa variable
subunit, and a 110- to 130-kD myosin-binding subunit. The myosin-binding subunit, when
phosphorylated, inhibits the enzymatic activity of MLC phosphatase, allowing the light
chain of myosin to remain phosphorylated, thereby promoting contraction. The smal1 G
protein RhoA and its downstream target Rho kinase play an important role in the regulation
of MLC phosphatase activity. Rho kinase, a serine/threonine kinase, phosphorylates the
myosin-binding subunit of MLC phosphatase, inhibiting its activity and thus promoting the
phosphorylated state of the myosin light chain. Pharmacological inhibitors of Rho kinase,
such as fasudil and Y-27632, block its activity by competing with the ATP-binding site on
the enzyme. Rho kinase inhibition induces relaxation of isolated segments of smooth muscle
contracted to many different agonists. In the intact animal, the pharmacological inhibitors of
Rho kinase have been shown to cause relaxation of smooth muscle.i9'20)
      In the previous study, the level of RhoA, an important protein that mediates Ca2'
sensitization,2') and ACh-•induced Ca2' sensitization in bronchial preparation of repeatedly
antigen challenged rats were significantly increased as compared with those of control rats,
The Ca2' sensitization was abolished by pretreatment with C3 toxin, Rho inhibitor. 22) These
findings strongly suggest that the mechanisms responsible for the augmented ACh-induced
contraction of the main bronchial smooth muscle might exist in post-muscarinic receptor
signaling including an augmented Ca2' sensitization.
                                  5
      On the other hand, there is increasing evidence that tumor necrosis factor-alpha
(TNF-alpha), one of the proinflammatory cytokines released from these inflammatory cells,
is directly linked to airway inflammation and hyperresponsiveness observed in asthma.23)
TNFaipha is elevated in the sputa and bronchoalveolar lavage fluid (BALF) of patients with
broRchial asthma.24'25) In mouse26) and guinea pig2') models of lung inflammation, increased
levels of TNF-alpha have been detected in the BALF of sensitized animals following
challenge with antigen. In addition, in vivo treatment of rat and human airways with
aerosolized TNF-alpha produced an enhanced increase in airway resistance similar to that
observed in asthma, when challenged with endogenous agonists.28'29) Pharmacological
evidence has also pointed towards an important role of TNF-alpha in AHR. TNF-alpha
receptor fusion protein, which can potently block endogenous TNF-alpha, was effective in
reducing both the enhanced airway reactivity and inflammatory cells inf7iltration into the
airways in sensitized guinea pigs and Brown-Norway rats in vivo.30) Moreover, incubation
with TNF-alpha of airvvay smooth muscle cells can produce an increase in agonist-stimulated
intracellular Ca2' release.3i) These observations suggest that TNF-alpha may be one of the
primary components responsible for the bronchial smooth muscle hyperresponsiveness
observed in asthma. Indeed, it has been demonstrated that TNF-alpha augments the
contraction of airway smooth muscle induced by agonists for muscarinic receptors in
humans and mice.32•33)
      Mitogen-activated protein kinase (MAPKs), a family of serine/threonine kinases,
consist of at least three distinct members: extracellular signal-regulated kinase (ERK, also
called p42/44 MAPK), p38 MAPK, and c-Jun NH,-terminai kinase (JNK).3`) MAPKs
regulate a variety of cellular responses, including inflammation, cell cycle progression,
proliferation, differentiation and protein synthesis.35) Recently, p38 and p42/44 MAPKs
were reported to be acrivated by proinflammatory cytokines such as TNF-alpha.36)
However, whether MAPKs are involved in the TNF-alpha-induced airway
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hyperresponsiveness is still unclear. The effects of inhibitors of p38 MAPK, MAPK-kinase
(MEK-1 and 2) and protein synthesis on the TNF-alpha augmented ACh-induced bronchial
smooth muscle contraction were therefore investigated. Furthermore, the phosphorylation of
p42/44 MAPK and upregulation of RhoA protein by TNF-alpha was investigated. The
effect of MEK inhibitor on TNF-alpha-induced upregulation of RhoA protein was also
elucidated by immunoblot analysis.
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Aims and Scopes
The special aims of the proposed research are:
In Chapter 1;
To investigate the alteration in acetylcholine (ACh)-induced Ca2" sensitization of bronchial
smooth muscle contraction in airway hyperresponsiveness (AHR), the ACh-induced
increases in cytosolic Ca2' ([Ca2']) level and contractile response were simultaneously
determined by using Fura-2 loaded bronchial smooth muscle.
Chapter 2;
To investigate the alteration in expression of RhoA in the bronchial smooth muscles of
repeatedly antigen challenged rats, Western blot and RT-PCR were performed. Moreover,
to investigate activation of RhoA, ACh-induced translocation from cytosolic to membrane
fraction was examined in freshly isolated single smooth muscle cells and bronchial smooth
muscle tissue of AHR rats.
Chapter 3 ;
To investigate the importtant muscarinic receptor subtype(s) in ACh-induced rat bronchial
smooth muscle contraction, pharmacological identification of the muscarinic receptor
subtype contributing to rat bronchial smooth muscle contraction was performed by using the
muscarinic receptor antagonists. Moreover, the muscarinic receptor subtype(s) participating
in the RhoA activation is still unclear. Thus, the aim of this study is also to identify the
receptor subtype which panicipates in the ACh--induced translocation of RhoA in rat
bronchial smooth muscle.
Chapter 4;
To investigate whether the tumor necrosis factor-alpha (TNF-alpha) augments ACh-induced
bronchial smooth muscle contraction, ACh-induced bronchial smooth muscle contraction by
pretreatment with TNF-alpha was measured in rats. I also investigated the effects of
SB203580 (p38 MAPK inhibitor), UO126 (inhibitor of p42/44 MAPK activation) and
cycloheximide (inhibitor of protein synthesis) on TNF-alpha-augmented ACh-induced
bronchial smooth muscle contraction. Furthermore, the phosphorylation of p42/44 MAPK
and upregulation of RhoA protein by TNF-alpha were investigated.
8
                           Chapter 1:
  Demonstration of augmented Ca2' sensitization in
   bronchial smooth muscle from antigen-induced
                airway hyperresponsive rats
Introduction
      Airway hyperresponsiveness (AHR) is a common feature of allergic bronchial
asthma, but the underlying mechanism(s) of AHR have yet to be elucidated. The importance
of AHR in the pathogenesis of asthma has been suggested by its relevance to the severity of
this disease.i'2) The authors previously reported that repeated antigen inhalation to actively
sensitized rats causes bronchial inflammation and marked AHR to inhaled consnictor
agonists.6) In this animal model of AHR, the isolated smooth muscle of the main bronchus
also exhibited hyperresponsiveness.6'8) Therefore, it is possible that the mechanisms
responsible for the AHR exist, at least in part, in the smooth muscle itself.
      It has been demonstrated that agonist stimulation increases myofilament Ca2'
sensitivity in variety types of permeabilized smooth muscles.37"39) In the present study, to
investigate the alteration in acetylcholine (ACh)-induced increase in Ca2+ sensitization of
bronchial smooth muscle contraction concurrent with the airway hyperresponsiveness
(AHR), the ACh-induced increases in cytosolic Ca2' ([Ca2']) level and contractile response
were simultaneously determined by using Fura-2 loaded bronchial smooth muscle.
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Experiment 1-1: Augmentation of acetylcholine
(ACh)-induced contractile response of the isolated
main bronchus fin repeatedly antigen challenged rats
Materials and Methods
Animals
      Male Wistar rats (6 weeks of age, specific pathogen-free, 170-190 g, Charles River
Japan, Inc) housed for appropriate time intervals in the animal center of Hoshi University
after their arrival. Constant temperature and humidity (22 Å} 1 OC, 55 Å} 10 9o) were
maintained with a fixed 12-hr }ight-dark cycle and free access to food and water.
Experiments were done according to the guiding principles for the care and use of laboratory
animals approved by the Animal Care Committee of Hoshi University.
Antigen challenge
      Animals were sensitized with 2,4-dinitrophenylated Ascaris suum extract
(DNP-Asc, 2 mg protein, s.c.) together with killed Bordetelta pertussis (2 x 10'O) as an
adjuvant and were boosted by DNP-Asc (O.5 mg protein, i.m.) 5 days later, according to the
method of Tada and Okumura.`O) Eight days after the first immunization, the rats were
challenged by inhaling DNP-Asc (6 mg proteinlmL, 5-6 mL) with an ultrasonic nebulizer
(TUR-3000, Nihon Kohden, Tokyo) for 40 min under conscious state in a plexiglass box
                                 10
(3oo x 2oo mm, height: 150 mm). Then the animals were subjected to 3 times repeated
antigenic challenge every 48 hr with the same inhalational challenge method descrived
above. These animals were used for experiments 24 hr after the final antigen•-challenge. Our
previous study revealed that the sensitization procedure to antigen used in the present study
had no significant effect by itself on the ACh responsiveness of the bronchial muscle and
muscarinic receptors property in rats.8) So in the present study, the age-matched
nonsensitized normal rats were used as control.
Functional study
      The airway tissues under the larynx to lungs were removed under chloral hydrate
(400 mg/kg, i.p.) anesthesia. About 4 mm length of the left main bronchus was isolated, the
epithelium was gently rubbed under a stereomicroscope and the resultant tissue ring
preparations were then suspended in a 5 mL organ bath at a resting tension of 1.0 g. The
isometrical contraction of the circular smooth muscle was measured with a
force-displacement transducer (TB-612T, Nihon Kohden, Japan). The organ bath contained
modified Krebs-Henseleit solution with the following composition (mM); NaCl 118.0, KCI
4.7, CaCl, 2.5, MgSO, 1.2, NaHCO, 25.0, KH,PO, 1.2 and glucose 10.0 (pH 7.4). The
buffer solution was maintained at 37 OC and oxygenated with 959o O,-59o C02. During an
equilibration period in the organ bath, the tissues were washed four times at 15-min
intervals and equilibrated slowly to a baseline tension of 1.0 g. Fifteen min after the last
washing, higher concentrations of ACh were successively added after attainment of a
plateau response to the previous concentration. In another series of experiments, bronchial
smooth muscle was depolarized with isotonic high K' solution prepared by iso-osmotic
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replacement of NaCl by KCI in the presence of 10-6 M atropine and 10'6 M indomethacin.
Statistical analysis
      All the data are expressed as the mean with S.E. Statistical significance of
difference was determined by Dunnett's multiple analysis or two way analysis of variance
(ANOVA).
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Resuks
      Fig. 1-1 shows the ACh responsiveness of the bronchial smooth muscle isolated
from control and repeatedly antigen challenged rats. ACh elicited a concentration-dependent
contractile response. The concentration-response curve to ACh was significantly shifted
upward after repeated antigenic challenge (pÅqO,05 by ANOVA). Application of isotonic
high K' solution (10, 30 and 60 mM) also elicited a concentration-dependent contractile
response in all tissues used. No significant difference in K' responsiveness was observed
between groups.
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Fig. 1-1
Acetylcholine (ACh; A) and high K' (B) concentration-response curves for contractile
responses of the isolated main bronchial rings from normal control (Control) and repeatedly
antigen challenged rats (Antigen-treated). Each point represents means Å} S.E. from 4-7
experiments. In the antigen-treated group, the ACh responsiveness of the main bronchial
smooth muscles was significantly (pÅqO.05, by ANOVA) augmented as compared to that in
the control group, whereas no significant difference in the K ' responsiveness was observed
between groups. *pÅqO.05 and **pÅqO.Ol vs, Control.
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Experiment 1-2: ACh-induced bronchial smooth
muscle tension and cytosolic Ca2' in the repeatedly
antigen challenged rats
Materials and Methods
Animals
      Male Wistar rats weighing 170-190 g (6 weeks of age), purchased from Charles
Nver Japan, Inc., were housed under standard laboratory conditions as described in
Experiment 1-1.
Antigen challenge
       Animals were sensitized and boosted with DNP-Asc as described in Experiment
1-1. Briefly, eight days after the first immunization, the rats were challenged by inhaling
DNP-Asc (6 mg proteinimL 5-6 mL) with an ultrasonic nebulizer (TUR-3000, Nihon
Kohden, Tokyo) for 40 min under conscious state in a plexiglass box (3oo x 2oo mm,
height: 150 mm). Then the animals were subjected to 3 times repeated antigenic challenge
every 48 hr with the same inhaiational challenge method descrived above. These animals
were used for experiments 24 hr after the final antigen--challenge. Our previous study
revealed that the sensitization procedure to antigen used in the present study had no
significant effect by itself on the ACh responsiveness of the bronchial muscle and
muscarinic receptors property in rats.7) So in the present study, the age-matched
nonsensitized normal rats were used as control.
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Measuring ACh-induced increase in [Ca2']i
       The resultant tissue ring preparation was then incubated in Ioading solution
Icontaining 10 mM Fu.ra-2 acetoxymethyl ester (Fura-2AM; Dojindo Laboratories,
Kumamoto Japan), O.02 9o cremophor EL (Nakalai Tesque, Kyoto, Japan) and 1 9o
dimetylsulfoxide in K-H buffer) for 3 hr at room temperature. After the Fura-2 loading, the
bronchial ring was washed with K-H buffer at 37 OC for 40 min to remove uncleaved
Fura-2AM. The smooth muscle layer of the bronchial ring was illuminated alternately (48
Hz) at the excitation wavelengths (340 and 380 nm) and the amount of 5oo nm fluorescence
induced by 340 nm excitation (F340) and that induced by 380 nm excitation (F380) was
monitored using a fiuorometer (CAF-1oo, Japan Spectroscopic, Japan) in a dark room. The
ratio of F340/F380 was measured as an index of [Ca2'],.9) The isometrical tension was
simultaneously measured by using a force-displacement transducer (TB-612T, Nihon
Kohden, Japan) at a resting tension of 1.0 g. After an equilibration period, the contractile
response and increase in [Ca2'], induced by ACh (10-5 and 10'3 M) were measured until
plateau responses were observed. Then the tissue was frequently washed out and
re-equilibrated (about 40 min). Thereafter, those responses induced by isotonic 60 mM K'
were also measured in the presence of 10 '6 M atropine. In individual tissue preparation, the
tension developed and increase in [Ca2']i induced by ACh were normalized by those induced
by 60 mM K', respectively.
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Fig. 1-2
The acetylcholine (ACh) concentration-response curves for contractile responses (A) and
increase in cytosolic Ca2' ([Ca2'],) levels (B) of the isolated bronchial smooth muscles from
nonsensitized normal control (Control; circles) and repeatedly antigen challenged rats (AHR;
squares). The 1oo 9o represent the 60 mM K'-induced sustained increases in tension and
[Ca2']i in individual tissue preparation, respectively. (C): The relationship between increases
in [Ca2']i levels (abscissa) and contractile responses (ordinate) at the stimulation with ACh
(10'5 and 10"3 M) in the bronchial smooth muscles from nonsensitized normal control
(Control; circle) and repeatedly antigen challenged rats (AHR; squares). Values are means Å}
S.E. from 8 experiments. *pÅqO.05 vs. Control.
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Discussion
      We previously reported that repeated challenge with aerosolized antigen to actively
sensitized rats causes a marked AHR to inhaled ACh.6'7'`') The isolated bronchial smooth
muscles from these animals also have hyperresponsiveness to ACh (Fig. 1-1). In the rat
model of AHR, it is also demonstrated that muscarinic receptor density and antagonist
affTinity of airway smooth muscle were within normal level.8) Moreover, no significant
difference in the bronchial smooth muscle contraction induced by depolarization with high
K' is observed between the AHR and control groups (Fig. 1-2). Thus, it is possible that the
mechanisms responsible for the AHR exisg at least in part, in the downstream pathway of
muscarinic receptor signaling. Airway smooth muscles are predominantly innervated by
vagal efferent nerves which release ACh when stimulated and subsequently activate
muscarinic ACh receptor. The activation of muscarinic receptors existing in airway smooth
muscle, which are mainly thought to be of the M, subtype,`2) results in smooth muscle
contraction by increasing the [Ca2']i through Ca2' release from the sarcoplasmic reticulum
and Ca2' influx from voltage-dependent (VDC) and receptor-operated Ca2" channels
(RoC).`3-`5) Therefore, the increased response to ACh of bronchial smooth muscle from the
AHR rats may be attributable to an enhanced Ca 2' mobilization by ACh in these tissues.
Altematively, because agonist-induced Ca2' sensitization of myofilaments at the contractile
response has been demonstrated in various types of smooth muscle including airways,9) an
augmentation of Ca2' sensitization induced by ACh may be involved in the enhanced
ACh-induced contraction of bronchial smooth muscle in the AHR rats. So, the correlation
between the contractile response and [Ca2'], of ACh-stimulated bronchial smooth muscle
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from the antigen-induced AHR rats was determined.
       In control rats tested in the current study, ACh elicited a concentration-dependent
contractile response and an increase in [Ca 2'], level (Fig. 1-2A and B). The Ca2' sensitizing
effect of the bronchial smooth muscle induced by ACh was small in the normal rats.
       In the present study, the ACh-induced contractile response of the bronchial smooth
muscle was significantly augmented in the AHR rats, although the increment in [Ca2']i was
within the control levels. The [Ca2'],-contraction relationship (Fig. 1-2C) indicates that
there is a positive comelation between these two parameters and that ACh induced a greater
contraction in bronchial smooth muscle from the AHR rat than that from the control animal
at a given [Ca 2+],. This is the first demonstration, to our knowledge of airway diseases, that
an augmentation of ACh-induced Ca2' sensitization might occur in bronchial smooth
muscle of the animals with antigen-induced AHR.
       Our previous study showing the increased contractility in response to Ca2' in
ACh-stimulated, but not in high K'-depolarized, bronchial smooth muscle from AHR rats
might also support the augmented ACh-induced Ca2' sensitization.8) Similarly, augmented
Ca2' sensitivity of myofilaments has been reported in vascular smooth muscle from
hypertensive animals. Satoh et al.`6) demonstrated the increased responsiveness to
5-hydroxytryptamine, but not to high K' depolarization, of intact coronary smooth muscle
of genetically hypertensive rats. Moreover, in the P-escin-perrnieabilized coronary smooth
muscle, the 5-hydroxytryptamine-induced Ca2' sensitizing effecq which was completely
blocked by GDPPS, was significantly greater in the hypertensive rats, although the
Ca2'-induced contraction was within Rormal levels.`6) Thus, they concluded that the
5-hydroxytriptamine-induced, G-protein-mediated Ca2' sensitization of myofilaments might
19
be involved in the pathogenesis of some diseases which have an altered smooth muscle
contractility such as asthma and hypertension.
      Although the exact mechanism responsible for the induction and/or augmentation of
Ca2' sensitization in bronchial smooth muscle is not known here, our present finding
strongly suggest an augmentation of ACh-induced myofilaments Ca2' sensitization in
bronchial smooth muscles from the AHR rats. The alteration in intracellular signal
transduction, but not in membrane receptor levels, of bronchial smooth muscle may account
for the nonspecific AHR which is a critical and common feature of allergic bronchial
asthmatics.
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                           Chapter 2:
Augmentation of RhoA expression and ACh-induced
RhoA activation in bronchial smooth muscle of the
            repeatedly antigen challenged rats
Introduction
      It has been demonstrated that agonist stimulation increases myofilament Ca2'
sensitivity in variety types of smooth muscles which were permeabilized by P-escin or
ct-toxin.3'-39) A participation of Rho protein in the agonist-induced Ca2' sensitization has
been suggested by many investigators.38'`6'`7) In Chapter 1, an existence of ACh-induced
Ca2' sensitization in smooth muscle contraction of bronchial strips and, funhermore, a
strong augmentation of this Ca2' sensitizing effect in the AHR state were demonstrated.
      In the present study, the expression levels of RhoA in the bronchial smooth muscle
of antigen-induced AHR rats were investigated by using Western blot and RT-PCR.
Moreover, to detemine whether the augmented Ca2' sensitization of bronchial smooth
muscle in AHR is mediated by a translocation, that is, activation of RhoA, the ACh-induced
translocation of RhoA from cytosol to the plasma membrane was investigated in bronchial
smooth muscle of AHR rats. Although the activation pathway of RhoA via membrane
receptors is not yet clear in smooth muscle, it is known that translocation of RhoA from
cytosol to plasma membrane occurs when RhoA is activated.47-49)
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Experiment 2-1: Upregulation of RhoA in bronchial
smooth muscle of the repeatedly antigen challenged
rats
Materials and Methods
Animals
      Male Wistar rats weighing 170-190 g (6 weeks of age), purchased from Charles
Mver Japan, Inc., were housed under standard Iaboratory conditions as described in
Experiment 1-1.
Antigen challlenge
      Animals were sensitized and boosted with DNP-Asc as described in Experiment
1-1. Breifly, eight days al'ter the first immunization, the rats were challenged by inhaling
DNP--Asc (6 mg protein/rni. 5-6 mL) with an ultrasonic nebulizer (TUR-3000, Nihon
Kohden, Tokyo) for 40 min under conscious state in a plexiglass box (300 x 2oo mm,
height: 150 mm). Then the animals were subjected to 3 times repeated antigenic challenge
every 48 hr with the same inhalational chalienge method descrived above. These animals
were used for experiments 24 hr after the final antigen-challenge. Our previous study
revealed that the sensitization procedure to antigen used in the present study had no
significant effect by itself on the ACh responsiveness of the bronchial muscle and
muscarinic receptors property in rats.8) So in the present study, the age-matched
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nonsensitized normal rats were used as control.
Western blot analysis
      To quantify the expression of RhoA proteiRs, Western blot was performed in the
homogenates of the main and intrapulmonary bronchi that were dissected from lung
parenchyma. Briefly, the samples (10 ptg of total protein per lane) were subjected to 12 9o
SDS - PAGE and the proteins were then electrophoretically transferred to a nitrocellulose
membrane. After blocking with 3 9o gelatin, the nitrocellulose membrane was incubated
with primary antibody (polyclonal rabbit anti-human RhoA lamino acids 119 - 132]; 1 :
2500 dilution, Santa Cruz). Then the membrane was incubated with horseradish
peroxidase-conjugated goat anti-rabbit IgG (1 : 25oo dilution; Amersham), detected by an
enhanced chemiluminescent system (Amersham) and analyzed by a densitometry system.
Thereafter, the primary and secondary antibodies were stripped and the membiane was
reprobed by using monoclonal mouse anti-glyceraldehyde-3-phosphate dehydrogenase
(GAPDH; 1 : 1000 dilution; Chemicon) to confrirm the same amount of proteins loaded.
Isolation of total RNA
      Twenty-four hr after the last antigen challenge, bronchial tissue preparations were
prepared in essentially the same manner described previously.8) Breifly, the airway system
below the main bronchi to the lungs was removed and immediately soaked in ice-cold,
oxygenated Krebs-Henseleit solution. The airways were carefu11y cleaned of adherent
connective tissue, blood vessels and 1ung parenchyma using stereomicroscope. The airway
epithelium was removed as completely as possible by gentiy rubbing with pair of
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keen-edged tweezers. Then the bronchial segments were quickly frozen with liquid
nitrogen, and the tissue was crushed using a CryopressiM (CP--100W; Niti-on, co. Ltd,,
Japan: 15 sce x 3). Tota1 RNA was isolated from each frozen tissue sample by the method
of acid guanidium thiocyanate/phenol/chloroform extraction50) and stored at -85 OC until
use.
RT-PCR analysis
      cDNAs were prepared from the tota1 RNA (O.5 ptg) by using a Takara RNA PCR
Kit (Ver. 2.1; Takara, Tokyo, Japan) in a tota1 volume of 20 ptL reaction buffer containing
10 mM Tris-HCI, pH 8.3, 50 mM MgCl,, 1 mM dNTP mixture, 1 U/mL RNase inhibitor,
2.5 geM random 9 mers, and O.25 U/mL avian myeloblastosis virus reverse transcriptase.
The reaction mixture was incubated for 10 min at 30 OC followed by 60 min at 42 OC to
initiate the synthesis of the cDNAs, Reverse transcriptase was inactivated at 99 OC for 5 min.
Then the RT reaction mixture (10 pL) was added by O,5 ptLof O.1 mM forward primer,
O.5 pL of O. 1 mM reverse primer, 4 yL of 10 X amplification buffer (1oo mM Tris-HCI,
pH 8.3, O.5 M KCI), 3 ptL of 25 mM MgCl ,, 3l.8 ptL of H,O, and O.25 pL of 5 U/mL Taq
polymerase. The PCR primers for rat RhoA were 5'-GTGATTGTTGGTGATGGAGC-3'
(sense) and 5'-erCGTGGCCATerCAAAAAC-3' (antisense).5') The PCR primers for rat
 glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were 5'-CCATCACTGCCACTC
-
AGAAGAC-3' (sense) and 5'-TACTCCTTGGAGGCCATGTAGG-3' (antisense), which
were designed from published sequences. The thermal cycle profile used in the present study
was l) denaturing for 30 sec at 95 OC, 2) annealing primers for 30 sec at 60 OC, 3) extending
the primers for 60 sec at 72 OC. The PCR amplifications were performed 25 cycles. A
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portion (10 pL) of the PCR mixture was subjected to electrophoresis on 2 qo agarose gel
(E-GelTM; Invitrogen, CA, USA) and visualized by densitometer (Atto Densitograph; Atto
Co,, Tokyo, Japan). The ratios of the corresponding RhoA/GAPDH were calculated as
indexes of RhoA mRNA levels.
Statistical ananyses
      All the data were expressed as the mean with S.E. Statistical significance of
difference was detemined by two-way analysis of variance (ANOVA).
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Results
      In the present study, anti-RhoA antibody was used to detect RhoA protein of rat
bronchial preparations. Representative immunoblots for RhoA and P-actin of bronchial
preparations from control and repeatedly antigen challenged rats are shown in Fig. 2-IA.
Immunoblotting with the antibody against RhoA showed a single 21 kD band, indicating the
existence of RhoA proteins in the rat bronchi. The ratios of corresponding RhoA!6-actin
were calculated and represented in Fig. 2-IB. The expression of RhoA protein in bronchial
preparation of the repeatedly antigen challenged rats was significantly increased as compared
with that of the control animals (pÅqO.05).
       Fig. 2-2 shows the expression of RhoA and GAPDH mRNAs in the rat bronchial
smooth muscle, as determined by RT-PCR using the total RNA estimated in preparations
from non-sensitized normal rats. The PCR amplifications were performed for 15, 20, 25,
30 and 35 cycles. Bands for RhoA (503 bp) and GAPDH (468 bp) were clearly detected in
the rat bronchial smooth muscle at a size close to that predicted (Fig. 2-2A). Both the band
intensities for RhoA and GAPDH were PCR amplification-cycle-dependently increased and
had nearly reached a plateau by 30-35 and 30 cycles, respectively (Fig. 2-2B), On the other
hand, the PCR products obtained without RT reaction had no distinct bands (lanes 6 and 1 1
of Fig. 2-2A), indicating that there was Ro genomic DNA contamination in the RNA
samples used in the present study.
       In order to estimate the extent of the expression of RhoA mRNA, the ratios of the
band intensity of RhoA mRNA to that of GAPDH were calculated. Our previous study
revealed that the antigen sensitization procedure used in the present study had no significant
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effect by itself on either the ACh responsiveness of rat bronchial smooth muscle or on their
muscarinic receptor propenies.7) So in the present study, age-matched non-sensitized
normal rats were used as controls. The PCR amplifications were peiformed for 25 cycles,
respectively, which showed submaximal but distinct bands (Fig. 2-3). As shown in Fig.
2-3, the level of mRNA expression of RhoA was significantly increased in the bronchial
muscle of repeatedly antigen-challenged rats. The band intensity for RhoA of the
antigen-treated rats (395.2 Å} 34.9, N=5) was significantly increased when compared to that
of the control animals (247.4 Å} 25.4, N=5, pÅqO.Ol), whereas the band intensity for
GAPDH was at an equivalent level (734.6 Å} 93.6 and 818.2 Å} 1 15.7, N=5, respectively).
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Fig. 2-1
The effects of repeated antigen challenge on RhoA expression in preparations of the main
bronchial smooth muscles. (A) Typical RhoA immunoblots of the main bronchial smooth
muscles obtained from normal control (lane: Lefi) and repeatedly antigen-challenged (lane:
Right) rats. A 21 kD band is corresponding to RhoA, and a 45 kD band is corresponding to
P-actin. (B) Relative densities of RhoA to P-actin (RhoAlP-actin) analyzed by densitometry.
The ratios of corresponding RhoAIP-actin in respective Ianes were calculated as indexes of
RhoA protein level from 4 experiments, respectively. Values are means Å} S.E. "pÅqO.05
compared with control group by Dunnett's multiple analysis.
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PCR CycRes
A) Detection of RhoA (lanes 2-6) and GAPDH (as an inner control; lanes 7-1 1) mRNAs by
RT-PCR in bronchial smooth muscle preparations of control (nonsensitized, normal) rats.
PCR amplifications for RhoA and GAPDH were perforrned for 20 (lanes 2 and 7), 25
(lanes 3 and 8), 30 (lanes 4 and 9) and 35 cycles (lane 5, 6, and 10, 11), respectively. The
predicted sizes of each PCR product are shown beside the photograph. Lanes 6 and 11
represent a negative control, where the RT reaction was performed in the absence of the
reverse transcriptase. Lanes 1 and 12 represent the DNA size marker (1oo bp DNA ladder).
B) The PCR cycle-dependency on the amplifications of the synthesized cDNAs for RhoA
(closed) and GAPDH (open). The total RNA experiments were performed on extracts from
5 different animals. Values are means Å} S.E.
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Fig. 2-3
The level of expression of RhoA mRNA in bronchial smooth muscle from nonsensitized
normal (Control) and repeatedly antigen-challenged rats (Antigen-treated). A) Typical
photographs of RT-PCR product bands for RhoA (upper) and GAPDH (lower) mRNAs.
The PCR amplifications were performed for 25 cycles, respectively. The bands were
scanned and the level of RhoA mRNA expression was expressed as density ratio of the
RhoA to the GAPDH bands and the data were summarized in B. The total RNA experiments
were performed on extracts from 5 different animals. Values are means Å} S.E. The
expression of RhoA mRNA is significantly increased in the bronchial smooth muscle of
antigen-treated rats as compared to that of control animals (pÅqO.Ol).
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Experiment 2-2: ACh-induced translocation of RhoA
in freshly isolated single smooth muscle cells of rat
bronchi
Materials and Methods
Animals
      Male Wistar rats weighing 170-190 g (6 weeks of age), purchased from Charles
River Japan, Inc., were housed under standard laboratory conditions as described in
Experiment 1-1.
Iso}ation of single bronchial smooth muscle cel}
      The left main bronchus of male Wistar rat (6 week old, specific pathogen-free) was
isolated under chloral hydrate (400 mg/kg, i.p.) anesthesia. The bronchial tissue was
transferred to ice-cold low calcium Krebs--Henseleit solution (LCKH: 139.0 mM NaCl, 5.4
mM KCI, O.2 mM CaCl,, 1.47 mM MgSO,, 1.4 mM NaHCO,, 2.8 mM N%HPO,, 1.47
mM KH,PO,, 11.0 mM glucose, pH 7.2), and adhering connective tissue and epithelium
were removed as described in Experiment 1-1. The smooth muscle strip was isolated from
cartilage and then incubated in buffer A (400 UlmL collagenase I, 7.5 UlmL elastase, 2.5
mg/mL BSA in LCKH) at 37 OC for 30 min. Then the smooth muscle strip was carefu11y
transferred to buffer B (200 UlmL collagenase L 15 U/mL elastase, 2.5 mg/mL BSA in
LCKH) and incubated for 30 min at 37 OC. The enzymatic reaction was stopped by
incubating it in buffer C (LCKH containing 10 9o feta1 bovine serum) for 10 min at 37 OC.
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After loosening the rnuscle strip by forceps, single srnooth muscle cells were obtained by
swaying the muscle strip gently in pre-warmed LCKH, and the cells were allowed to attach to
a slide glass by incubat:ing the cells at 37 OC for 90 min. The cells were then equilibrated in
normal Krebs-Henselejt solution (118.0 mM NaCl, 4.7 mM KCI, 2.5 mM CaCl,, l.2 mM
MgSO,, 25.0 mM NaHCO,, 1.2 mM KH,PO,, 10.0 mM glucose, pH 7.4) at 37 eC for 1 hr.
After the equilibration period, isolated single smooth muscle cells were stimulated with 10"3
M ACh or untreated. Ten minutes later, the cells were fixed with 3.5 9o formaldehyde and
subsequently permeabilized with O.5 9o Triton X-1oo (for 10 min at room temperature,
respectively). After blocking with 3 9o BSA in PBS (1 lir), cells were incubated with rabbit
anti-RhoA antibody (1: IOOO; Cat. No. sc-179; Santa Cvruz Biotechnology, Inc., Santa Cruz,
CA, USA) and mouse anti-or-smoc;th muscle actin antibody (1: 400; Cat. No. A-2547;
Sigma, St. Louis, MO, USA) in blocking buffer at 37 OC for 1 hr. Cells were frequently
washed with PBS and. incubated with Alexa Fluor 488-conjugated goat anti-rabbit IgG
antibody (}.: 2oo; Cat. No. A-1 1034; Molecular Probes, Inc., Engen, OR, USA) and Alexa
Fluor 546-conjugated goat anti-mouse IgG antibody (1: 200; Cat. No. A-11030; Molecular
Probes, Inc.) in blocking buffer at 37 OC for 1 hr. -Arfter frequent washing with PBS,
coversiips were mounted on the slides with DABCO (Sigma). Immunostained cells were
visualized by a confocal laser microscope (Radiance21oo; Bio-Rad Laboratories, Hercules,
CA, USA), The cellular peripheral to cytosolic ratios of the immunolabeled RhoA proteins
were assessed for ct-actin positive celis, that is, bronchlal smooth muscle cells. In brief, 2
line scans, each of the middlle point berween the nucleus edge and keen-edged cell surface,
were performed across the width of a cell. By using a densitometry system (Atto
Densitograph Software for the Macintosh ver. 4.0; Atto Co., Tokyo), pixel intensities over
                                    32
the outer 15 9o of each cell width were taken as an index of peripheral RhoA, whereas those
over the remaining central 70 9o of the cell width were estimated as cytosolic RhoA.`9'52) Ten
cells were analyzed for each animal and the average was determined as N=1.
Statistical analyses
      All the data were expressed as the mean with S.E. Statistical significance of
difference was determined by the unpaired Student's t-test.
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Res"1ts
      As shown in Fig. 2-3 B and C, the ceiiular distribution of RhoA proteins at rest
was observed uniformly in the cytosolic space with no staining in the nucieus. ACh
stirnulation induced a relocalization of RhoA proteins to the celi periphery (Fig. 2-3 F and
G), which means traRslocation of RhoA proteins to the cell membrane. Typical positions of
line scans and surface plots at rest and stimulated by ACh are shown in Fig. 24, A-D.
Based on the results of sui7face plots (Fig. 2-4 C and D), the peripheral to cytosolic ratios of
immunostained intensities were calculated as described above and are summarized in Fig.
2-4 E. The peripheral to cytosolic ratio of RhoA proteins was significantly increased by
ACh stimulation (3.02 Å} O.47 from O.62 Å} O.02 of control, pÅqO.Ol), indicating that ACh
induced a translocation of RhoA to the plasma membrane in single bronchial smooth muscle
celP.s of the rat.
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Fig. 2-3
Typical confocal immunofluorescent image of RhoA and ot--actin in freshly isolated rat
bronchial smooth muscle cells at rest (Lqfi panels) and stimulated by 10"i M
acetylcholine ÅqACh) (for 10 min, Right pctnels). A and E: transmitted light images; B and
F: RhoA immunostainings indicated by green fluorescence of Alexa Fluor 488; C and G:
overlays of A and E with B with F, respectively; and D and H: ot-actin immunostainmgs
indicated by red fluorescence of Alexa Fluor 546. 0riginal magnification: x 600.
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Experiment 2-3: Augmentation of ACh-induced
translocation of RhoA in bronchial smooth muscles
of the repeatedly antigen challenged rats
Materials and Methods
Animals
      Male Wistar rats weighing 170-190 g (6 weeks of age), purchased from Charles
River Japan, Inc., were housed under standard laboratory conditions as described in
Experiment 1-1.
Sensitization and antigenic challenge
      Animals were sensitized and repeatedly challenged with 2,4-dinitrophenylated
Ascaris suum antigen (DNP-Asc) by the method described in Experiment 1-1. Age-matched
non-sensitized normal animals were used as a control (Experiment 1-1).
Functional studies
      Approximately 4 mm Iengths of the left main bronchus were isolated. The isometric
contraction of the circular smooth muscle was measured at a resting tension of 1.0 g as
described in Experiment 1-1.
Preparation of membrane and cytosolic fractions
      Bronchial tissue preparations were prepared by the method described in Experiment
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2-1 with minor modifications. In brief, the airway tissues below the main bronchi were
removed and immediately soaked in ice-cold, oxygenated Krebs-Henseleit solution (in mM:
NaCl 118.0, KCI 4.7, CaCl, 2.5, MgSO, 1.2, NaHCO, as, KH,PO, 1.2, glucose 10; pH
7.4). The airways were carefu11y cleaned of adhering connective tissues, blood vessels and
lung parenchyma under stereomicroscopy. The epithelium was removed as much as
possible by gently rubbing with sharp-edged tweezers. Then the bronchial tissue segments
(containing main and intrapulmonary bronchi) were equilibrated in oxygenated
Krebs-Henseleit solution (37 OC) for 60 min with 10 min washout intervals. After the
equilibration period, the tissue segments were stimulated by a concentration of ACh for the
indicated time. The reaction was stopped by quickly freezing with liquid nitrogen and the
tissue was then homogenized with Physcotron (Niti-on, Co. Ltd., Japan: six times for 5
sec; level max) in 2 mL ice-cold homogenization buffer with the following composition mM:
Tris-HCI (pH 7.5) 10, MgCl, 5, EDTA Z sucrose 250, DTT 1, 4(2-aminoethyl)
benzenesulphonyl fluoride 1, 20 ptg/mL leupeptin and 20 ptg/mL aprotinin. The tissue
homogenate was centrifuged (105,OOO x g, 4 OC for 30 min) and the supernatant was
collected as the cytosolic fraction. The pe11et was resuspended in 3 mL homogenization
buffer and recentrifuged (105,OOO x g, 4 OC for 30 min). The resuhant pe11et was
resuspended in 2 mL ice-cold homogenization buffer containing 1 9o (v/v) Triton X-1oo and
1 9o (w/v) sodium cholate and used as the membrane fraction. These preparations were
stored at -80 OC until use. The protein concentrations of these preparations were determined
by the method of Lowry et al.53) in triplicate with bovine serum albumin as a standard.
Western blots
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      Imrnunoblouing was performed in the preparations obtained from the AHR rats
(sensitized and repeatedly antigen-challenged) and normal control rats as described above.
Briefly, the membrane and cytosolic fractions were dissolved in SDS sample buffer and
heated at 1oo OC for 4 min. The samples (10 pg protein per lane) were subjected to 159o
SDS-PAGE. Proteins were then electrophoretically transferred for 4 hr onto nitrocellulose
membranes (Hybond-ECL, Amersham, Liule Chalfont, U.K.) in cold transfer buffer (20 9o
methanol containing Tris 25 mM and glycine 192 mM). After repeated washing with Tris
buffer (Tris 20 mM, NaCl 5oo mM, pH 7.5) containing O.1 9o (v/v) Tween 20 CITBS), the
nitrocellulose membranes were incubated with blocking buffer (3 9o gelatin in TTBS) for 1.5
hr at room temperature. The nitrocellulose membranes were then incubated with polyclonal
rabbit anti-RhoA (amino acids 119 - 132; 1 : 30oo dilution; Santa Cruz Biotechnology,
Santa Cruz, Califomia, U.S.A.) in antibody buffer (1 9o gelatin in TTBS) for 12 hr at room
temperature. The nitrocellulose membranes were then washed five times (each for 15 min)
with TTBS. They were incubated with horseradish peroxidase (HRP)-conjugated goat
anti-rabbit IgG (1 : 5ooO dilution; Amersham) for 1.5 hr at room temperature, and then
washed five times with TTBS. The blots were detected with an enhanced chemiluminescent
method (ECL System; Amersham) and quantified by densitometry (Atto Densitograph
Software ver. 4.0; Atto Co., Japan). To normalize the RhoA contents to an internal control
protein, P-actin, immunobloning was also performed on the same gel by using monoclonal
mouse anti-P-actin N-terminal (1 : 5000 dilution; Sigma, St. Louis, Missouri, U.S.A.) and
goat anti-mouse IgG (1 : 5000 dilution; Amersham). Under the above conditions, a linear
relationship between the band density of RhoA and amounts of loaded proteins was found
for protein quantities ranging between 5 and 25 ptg.22) Simi1ar results were obtained for
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P-actin. The ratios of corresponding RhoAIP-actin in each lane were calculated as indexes of
RhoA protein levels. The per cent of membrane/total RhoA was calculated according to the
formula (membrane RhoA/P-actin)1[(membrane RholP-actin)+(cytosolic RhoAIP-actin)].
Statistical analyses
      All data are expressed as mean with S.E.
determined by Dunnett's multiple comparisons
(ANOVA).
Statistical significance of differences was
 test or two-way analysis of variance
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Results
      In normal rats, both the membrane and cytosolic fractions of bronchial smooth
muscle contained RhoA proteins (RhoA/P-actin, N=5: O.19 Å} O.08 and O.47 Å} O.07,
respectively) at resting state (no ACh stimulation). The ratio of membrane to total RhoA at
resting state was 25.7 Å} 6.9 9o. ACh (10'3 M) stimulation elicited rapid increases in tension
and RhoA contents in the membrane fractions, while cytosolic RhoA was decreased (Fig.
                             -32-5). One minute after addition of 10
                           M ACh to the intact (non-permeabilized) bronchial
smooth muscle, tension reached 53.6 Å} 5.5 9o of the maximal ACh-induced contraction
(N=5); this was accompanied by an increase in membrane RhoA, increasing from the
resting value of 25.7 Å} 6.9 9o (N=5) to 63.5 Å} 7.89o membrane/tota1 RhoA (N=5, pÅqO.05).
Thereafter, both contraction and membiane RhoA gradually increased and reached plateaux
at 10 - 20 min after ACh stimulation (Fig. 2-5C).
      As shown in Fig. 2-6, ACh also induced concentration-dependent increases in
tension and membrane RhoA. The ACh (10-3 M)-induced increase in membrane RhoA (69.4
Å} 8.6 9o membraneltotal RhoA, N=5) was completely blocked by pretreatment with 1 pM
atropine (29.1 Å} 4.4 9o membraneltota1 RhoA, N 4; pÅqO.05).
      In bronchial smooth muscle of the AHR iats, basal RhoA contents (no ACh
stimulation) estimated by RhoA/P-actin were significantly greater (O.68 Å} O.17 in membrane
and 1.13 Å} O.23 in cytosolic fractions, N=5) than those of normal animals (O.19 Å} O.08 and
O.47 Å} O.07, respectively; pÅqO.05), whereas the ratio of membrane to total RhoA was
within normal levels (33.3 Å} 7.2 9o; Fig. 2-7). As shown in Fig. 2-7, ACh elicited a
concentration-dependent translocation of RhoA in both groups. Interestingly, the ACh
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concentration-response curve for translocation of RhoA in the
shifted to the left as compared to that in normal animals (pÅqO.05
AHR rats was signi
; Fig. 2-7).
ficantly
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Fig. 2--5
Time course of acetylcholine (ACh)-induced translocation of RhoA in bronchial smooth
muscle of non-sensitized normal rats. The isolated main and intrapulmonary bronchi were
stimulated by ACh (10 -3 M), and homogenized to prepare cytosolic and membrane fractions
after stopping the reaction by liquid nitrogen at the time indicated. Western blouing was
performed by using these fractions both on RhoA and P-actin in the identical transferred
membrane. (a) Representative Western blots of membrane RhoA (21 kD) and P-actin. (b)
Relevance of the time courses of ACh (10-3 M)-induced increase in membrane RhoA and
decrease in cytosolic RhoA. (c) Relevance of the time courses of ACh (10-3 M)-induced
contraction and translocation of RhoA. Values are means Å} S.E. from 5 experiments in
duplicate. *pÅqO.05 and **pÅqO.Ol vs. respective time O (no stimulation).
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Fig. 2-6
The concentration-dependence of acetylcholine (ACh)-induced translocation of RhoA in
bronchial smooth muscle of non-sensitized noimal rats. The isolated main and
intrapulmonary bronchi were stimulated by ACh (10'6-10-3 M), and homogenized to prepare
cytosolic and membrane fractions after stopping the reaction by liquid nitrogen 10 min after
stimulation. Western blotting was performed by using these fractions both on RhoA and
P-actin in the identical transferred membrane. The ACh-induced translocation of RhoA
seems correlated with contraction induced by the identical concentrations of ACh. Values
are means Å} S.E from 5 experiments in duplicate. *pÅqO.05 and "*pÅqO.Ol vs. respective
basal level (no stimulation).
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Fig. 2-7
Acetylcholine (ACh) concentration-response curves for translocation of RhoA in bronchial
smooth muscles from non-sensitized normal (Control) and repeatedly antigen challenged
rats (Antigen-treated). The isolated main and intrapulmonary bronchi were stimulated by
ACh (10'6--10-3 M), and homogenized to prepare' cytosolic and membmne fractions after
stopping the reaction by liquid nitrogen 10 min after stimulation. Western blouing was
performed by using these fractions both on RhoA and P-actin in the identical transferred
membrane and the percent of membrane to total RhoA was calculated. Values aie means Å}
S.E. from 5 experiments in duplicate. The ACh-induced translocation of RhoA was
significantly augmented in antigen-treated group (*pÅqO.05 by ANOVA).
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Discussion
        We previously reported that repeated challenge of actively sensitized rats with
aerosolized antigen causes distinct airway inflammation and marked AHR to inhaled ACh
in vivo.`') The isolated bronchial smooth muscle from these animals also displays
hyperresponsiveness to ACh. More recently, a marked augmentation of ACh-induced,
RhoA-mediated Ca2' sensitization has been demonstrated in bronchial smooth muscie of this
animal model of AHR in Chapter 1.22'5`) In the present study, ACh-induced translocation of
RhoA in freshly isolated single bronchial smooth muscle cells was investigated. Moreover
translocation of RhoA in intact bronchial smooth muscle of AHR rats was compared with
that of normal animals to demonstrate an augmented activation of RhoA at antigen-induced
AHR.
        In the present study, the ratio of membrane to total RhoA of normal rats at resting
state (25.7 Å} 6.9 9o) is approximately equal to that reported in the portal vein and ileum,`8)
indicating a successful separation of the membrane RhoA proteins. ACh stimulation elicited
time- and concentration--dependent increases in tension and RhoA content in the membrane
fraction, while cytosolic RhoA was decreased (Figs. 2-5 and 2-6). These findings indicate
that ACh induces translocation of RhoA from the cytosol to the membrane fthat is an
activation of RhoA`7'`9)] in rat bronchial smooth muscle via an activation of muscarinic
receptors. Furthermore, the translocation of RhoA induced by ACh might be a parallel event
to the induction of contraction in the intact bronchial smooth muscle of the rat (Figs. 2-4
and 2-5).
        ACh-induced bronchial contraction was significantly augmented in the repeatedly
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antigen-challenged rats, indicating that reproducible AHR occurs at the level of bronchial
smooth muscle after repeated antigen inhalation (Chapter 1). In this animal model of AHR,
basal RhoA content (no ACh stimulation) was significantly greater than that of normal
animals (Experiment 2-1). Although the basal content of bronchial membrane RhoA was
increased in AHR, the functional role of this membrane-associated RhoA is unclear. If this
membrane-associated RhoA were involved in the Ca2' sensitization of contractile
apparatus, an increase in intracellular Ca 2' concentration of smooth muscle (by non-receptor
stimulation) would induce further contraction. However, our laboratory previously
demonstrated that the K'-depolarization-induced contraction of intact (non-permeabilized)
bronchial smooth muscle and the Ca2'-induced contraction of P-escin permeabilized
bronchial smooth muscle were within normal levels even in AHR.22'54) Gong et al.`7)
suggested that membrane-associated RhoA existed in at least two states, resting and
activated states, in the rabbit portal vein. In the absence of ACh stimulation, a large
proportion of the membrane-associated RhoA observed in the hyperresponsive bronchial
smooth muscle may be in the resting state.
        As in the normal group, ACh stimulation induced concentration-dependent
translocation of RhoA to the membrane in bronchial smooth muscle from AHR rats (Fig.
2-7). Interestingly, the ACh-induced translocation of RhoA was significantiy enhanced in
bronchial smooth muscle of AHR rats (Fig. 2-4). Thus, in addition to the upregulation of
RhoA pr,oteins (Experiment 2-1), it is suggestive that RhoA activation pathway(s) via
muscarinic receptors of bronchial smooth muscle might be functionally augmented in AHR
in rats. Although the detailed mechanism of activation pathway of RhoA in airway smooth
muscle is not clear at present, an involvement of heterotrimeric G protein(s) has been
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suggested.55'56) we also demonstrated an upregulation of heterotrimeric G proteins,57) but
not muscarinic receptors,7) in bronchial smooth muscle in the AHR model. Therefore, it is
possible that enhanced signaling by the increased heterotrimeric G proteins may be involved
in the augmented activation of RhoA in AHR in rats.
        In conclusion, ACh induced a RhoA translocation to plasma membrane - i.e. an
activation of RhoA - in rat freshly isolated bronchial smooth muscle cells and tissues. The
level of ACh-induced RhoA translocation was markedly increased in AHR as compared to
that in the control group. Our data suggest that the augmented activation of RhoA observed
in the hyperresponsive bronchial smooth muscle might be responsible for the enhanced
ACh-induced Ca2' sensitization of bronchial smooth muscle contraction at the AHR in rats.
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                          Chapter 3
  Involvement of mucarinic receptor subtype in
ACh-induced contraction and RhoA translocation
            in rat bronchial smooth muscle
Introduction
       In airway, three muscarinic receptor subtypes (M,, M, and M,) have been
functionally characterized, and the M, muscarinic receptor is believed to be the main receptor
subtype contributing to airway smooth muscle contraction.`3) Similarly, the existence of
three muscarinic receptor subtypes is also demonstrated in rat airvvays by using ligand
binding analysis.58) However, the muscarinic receptor subtype contributing to the
acetylcholine (ACh)-induced contraction of rat bronchial smooth muscle is unclear. Thus, in
this study, pharmacological identification of the muscarinic receptor subtype contributing to
rat bronchial smooth muscle contraction was performed by using the muscarinic receptor
antagonists, pirenzepine (an M, antagonist), methoctramine (an M, antagonist) and
4-diphenylacetoxy N-methylpiperidine (4DAMP; an M, antagonist).
      It is known that RhoA is translocated from cytoplasm to cell membrane in bronchial
smooth muscle when activated by ACh stimulation. In this study, the effects of selective
muscarinic receptor antagonist methoctramine, 11-[[2-[(Diethylamino)methyl]-1-
-
piperidinyl]-5,11-dihydro-6H-pyrido[2,3-b]benzodiazepin-6-one (AF-DXI16; an M,
antagonist) and 4-DAMP on the ACh-induced rat bronchial smooth muscle contraction and
increase in membrane-associated RhoA were investigated to elucidate the muscarinic receptor
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subtype participating in these responses. The muscarinic M,
detected by using RT-PCR in rat bronchial smooth muscle.
and M3 receptors were also
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Experiment 3-1: Characterization of muscarinic
receptors in ACh-induced bronchial smooth muscle
contraction
Materials and Methods
Animals
      Male Wistar rats weighing 170-190 g (6 weeks of age), purchased from Charles
Nver Japan, Inc., were housed under standard laboratory conditions as described in
Experiment 1-1.
Functionall study
      The animals were killed by exsanguination from abdominal aorta under anesthesia
with chloral hydrate (400 mgtkg, i.p.). About 4 mm length of the left main bronchus was
isolated by the method as described in Experiment 1-1. The isometrical contraction of the
circular smooth muscle was measured with a force-displacement transducer (TB-612, Nihon
Kohden, Japan) and recorder (SS-250F, Sekonic, Japan). The organ bath contained
modified Krebs-Henseleit solution. The buffer solution was maintained at 37 OC and
oxygenated with 95 9o O,-5 9o CO,. After an equilibration period, the
concentration-response curve to ACh (10"-10-3 M) was constructed cumulatively. After
repeated washing-out, the tissue was re-equilibrated (for about 60 min) and then the
concentration-response curve to ACh (10'7-10-3 M) was made after a 40 min preincubation
with pirenzepine (Sigma, St. Louis, USA; 10-6-10'` M), methoctramine (RBI, Natick,
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USA; 10'6-10-` M) or 4-DAMP (RBI, Natick, USA; 10'9-10"' M).
      Competitive antagonism in the ACh-induced contraction experiments was assessed
according to Arunlakshana and Schild (1959). The EC50 (concentration required to elicit 50
9o of the maximum contraction) was determined for each tissue with and without increasing
concentration of the antagonists. Concentration ratios were calculated as the EC50 in the
presence of the antagonist divided by that in the absence of the antagonist. A Schi}d
regression was determined by ploning log (concentration ratio - 1) versus -log [antagonist].
The pA, value (affinity of a compound for a receptor) is the intercept of this regression line
with the abscissa. The pA, value and slope were calculated for each individual experiment
and the mean value Å} S.E. are shown.
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Results
      ACh elicited a concentration-dependent contractile response in al1 tissues in the
absence of the antagonist; the maximal contraction was 1.24 Å} O,11 g of tension and the
negative logarithm of EC50 (pD,) was 5.22 Å} O.09 (N=17). Preincubation with the
muscarinic receptor antagonists resulted in concentration-dependent rightward shifts of the
concentration-response curves to ACh (Fig. 3-1). The results of Schild analysis are
summarized in Fig. 3-2 and Table 1. The ACh-induced bronchial smooth muscle contraction
could be antagonized with high aff1inity by 4-DAMP and with low affinity by pirenzepine
and methoctramine.
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Fig. 3--1
Concentration-response curve to acetylcholine following preincubation of the bronchial ring
with various concentrations of selective muscarinic receptor antagonists, pirenzepine
(Upper; N=6), methoctramine (Middle; N=6) and 4-DAMP (Lower; N=5). Values are
means Å} S.E.
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Fig. 3-2
Arn1akshana-Schild plot for the antagonism of acerylcholine-induced contraction of rat
bronchial smooth muscle by pirenzepine (N=6), methoctramine (N=6) and
4-diphenylacetoxy-N- methy!piperidine methiodide (4-DAMP; N=5). Each point represents
the mean Å} S.E. Lines represent a linear fit through the data. CR: concentration ratio.
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Table 1
Inhibition of acetylcholine-induced contraction of rat bronchial smooth muscle by
muscarlnlc receptor antagonlsts.
Antagonist pA2 value slope correlation
Pirenzepine (N=6)
Methoctramine (N=6)
4-DAMP (N=5)
7.03 Å} O.06
5.91 Å} O. 14
8.80 Å} O. 10
O.70 Å} O.02
O.53 Å} O. 14
O.70 Å} O.04
O.99
O.99
O.99
Values of pA2 and slope represented are means Å} S.E.
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Experiment 3-2: Characterization of muscarinic
receptors in ACh-induced translocation of RhoA in
rat bronchial smooth muscle
Materials and Methods
Animals
     Male Wistar rats weighing 170-190 g (6 weeks of age), purchased from Charles
Nver Japan, Inc., were housed under standard laboratory conditions as described in
Experiment 1-1.
RT-PCR analysis
     The main and intrapulmonary bronchial tissues weie quickly frozen with liquid
nitrogen, and the tissues were crushed to pieces by CryopressTM (CP-1ooW; Niti-on, Co.
Ind., Japan: 15 sec x 3). Total RNA was isolated from each frozen tissue powder by using
TRI@ REAGENT (Sigma) and stored at -85 OC unti1 use. cDNAs were prepared from the
tota1 RNA (1 ptg) by reverse transcriptase reaction in a tota1 volume of 50 psL reaction buffer
containing 10 mM Tris-HCI, pH 8.3, 50 mM MgCl ,, 1 mM dNTP mixture, 1 U/mL RNase
inhibitor, 2.5 ptM random 9 mers, and O.25 U/mL avian myeloblastosis virus reverse
transcriptase. The reaction mixture was incubated for 5 min at 25 OC followed by 60 min at
42 OC to initiate the synthesis of the cDNAs. Reverse transcriptase was inactivated at 70 OC
for 5 min. Then the RT reaction mixture (1 pL) was added by 1 ptL of 1 pM forvvard primer,
1 ptL of 1 pM reverse primer, 3 ptL of 2 X PCR Master Mix (O.05 units/ptL Taq DNA
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polymerase, 4 mM MgCl , and O.4 mM of each dNTPs; Fermentas Life Science). The PCR
primers for rat muscarinic M, receptor used were 5'-GGGTCCTTTCCTTCATCCTcrG-3'
(sense) and 5'-AACACAGGTTTCAGTCACGCCG-3' (antisense). The PCR primers for
rat muscarinic M, receptor used were 5'-GAAAGAAGGAGAGGCATACCGC-3' (sense)
and 5'-CAGTTCAGTGTTCCCCATCACG-3' (antisense), which were designed from
published sequences (NM-031016 and NM-O12527), The thermal cycle profile used in the
present study was 1) denaturing for 3 min at 95 OC, 2) annealing primers for 15 sec at 55 OC,
3) extending the primers for 1 min at 72 OC. The PCR amplifications were performed for 30
cycles. The PCR mixtures were subjected to electrophoresis on 2 9o agarose gel with DNA
MW standard marker 1oo bp DNA ladder (Takara Bio Inc.) and visualized by densitometer
(Atto Densitograph; Atto Cvo., Tokyo, Japan).
Preparation of membrane and cytosolic fractions
     Membrane and cytosolic fractions of bronehial tissue were prepared by the method
described in Experiment 2-3 with minor modifications. In brief, the airway tissues below
the main bronchi were removed and immediately soaked in ice-cold, oxygenated
Krebs-Henseleit solution. The airways were carefully cleaned of adhering connective
tissues, blood vessels and lung parenchyma under stereomicroscopy. Then the bronchial
tissue was equilibrated in oxygenated Krebs-Henseleit solution (37 OC) for 60 min with 10
min washout intervals. After the equilibration period, the tissue segments were stimulated
by an indicated concentration of ACh (10'3 M) for 20 min. The reaction was stopped by
quickly freezing with liquid nitrogen and the tissue was then homogenized in 1 mL of
ice-cold homogenization buffer with the following composition (mM): Tris-HCI (pH 7.5)
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10, MgCl, 5, EDTA Z sucrose 250, dithiothreitol 1,4-(2-aminoethyl) benzenesulphonyl
fluoride 1, 20 ptgtmL leupeptin and 20 ptgtmL aprotinin. This homogenate was used to
quantify the expression of RhoA. The tissue homogenate was centrifuged (105,OOO x g,
4 OC for 30 min) and the supematant was collected as the cytosolic fraction. The pellet was
resuspended in 3 mL homogenization buffer and recentrifuged (105,OOO x g, 4 OC for 30
min). The resultant pe11et was resuspended in 2 mL ice-cold homogenization buffer
containing 1 9o (v/v) Triton X-1oo and 1 9o (w/v) sodium cholate and used as the membrane
fraction. These preparations were stored at -80 OC unti1 use.
Western blots
      To quantify the ACh-induced increase in membrane-associated RhoA,
immunoblotting was performed as described in Experiment 2-3. Briefly, the samples (10
ptg protein per lane) were subjected to 15 9o SDS-PAGE. Proteins were then
electrophoretically transferred for 4 hr onto PVDF membranes (Hybond-ECL, Amersham,
linie Chalfont, U.K.) in cold transfer buffer (20 9o methanol containing Tris 25 mM and
glycine 192 mM). After repeated washing with Tris buffer (Tris 20 mM, NaCl 5oo mM, pH
7.5) containing O.1 9o (v/v) Tween 20 ('ITBS), the PVDF membranes were incubated with
blocking buffer (3 9o gelatin in TTBS) for 1.5 hr at room temperature. The PVDF
membranes were then incubated with primary antibody [polyclonal rabbit anti-RhoA (amino
acids 119-132; 1: 3000 dilution, Santa Cruz Biotechnology) in antibody buffer (1 9o gelatin
in TTBS) for 12 hr at room temperature. The PVDF membranes were then washed five
times (each for 15 min) with TTBS. They were incubated with horseradish peroxidase
(HRP)-conjugated goat anti-rabbit IgG (Amersham) for 1.5 hr at room temperature, and
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then washed five times with TTBS. The blots were detected with an enhanced
chemiluminescent method (ECL System; Amersham) and quantified by densitometry (Atto
Densitograph Software ver. 4.0; Atto Co., Japan). To normalize the RhoA contents to an
internal control protein, B-actin, immunoblotting was also performed on the same gel by
using monoclonal mouse anti- P-actin N-terminal (Sigma, St. Louis, Missouri, U.S.A.) and
goat anti-mouse IgG (Amersham). Under the above conditions, a linear relationship between
the band density of RhoA and amounts of loaded proteins was found for protein quantities
ranging between 5 and 25 ptg.59) Similar results were obtained for P-actin. The ratio of
corresponding RhoAl P-actin in each lane was calculated as indices of RhoA protein levels.
The membraneltotal RhoA in each animal sample was calculated according to the formula
(membrane RhoA/P-actin)/[(membrane RhoAIP-actin)+(cytosolic RhoA16-actin)l.
Statistical analysis
      All the data were expressed as the mean with S.E. Statistical analyses were
performed by one or two-way ANOVA with post-hoc tests performed using a
BonferronilDunn's test.
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Results
      Fig. 3-3 shows the expression of muscarinic M, and M3 receptor mRNAs in rat
bronchial smooth muscle, as determined by RT-PCR using total RNA. The PCR
amplifications were performed for 30 cycles. The expected sizes of the bands for M, (383
bp) and M3 (511 bp) were clearly detected in rat bronchial smooth muscle.
      To determine the ACh-induced increase in membrane-associated RhoA in rat
bronchiai smooth muscle, immunoblottings were performed in the homogenates of the main
and intrapulmonary bronchi which were dissected free from lung parenchyma. As shown in
Fig. 34, immunoblotting with RhoA antibody of membrme fraction gave a single band
with 21 kD molecular weight indicating existence of RhoA protein in the rat bronchial
smooth muscle (Fig. 3-4A). The level of membrane RhoA was significantly increased by
ACh (10-3 M) stimulation (Fig. 3-4B). No significant difference in the ACh-induced
increase in membrane-associated RhoA in bronchial smooth muscle was observed between
the control and methoctramine- or AF-DXI16-treated groups. However, the ACh-induced
increase in membrane-associated RhoA was significantly attenuated by treatment with
4-DAMP.
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Lane 1 2 3 4 5
-
511 bp (M,-R)
•- 383 bp (M2-R)
Fig. 3--3
Expression of M, and M3 receptor mRNA in the rat bronchial smooth muscle. The PCR
amplifications were performed for 30 cycles. The lane 1 was represented 100 bp DNA
ladder marker. The predicted sizes of the bands for M, (lanes 2 and 3; 383 bp) and M.,
(tanes 4 and 5, 51 1 bp) receptors were detected.
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The effects of selective muscarinic receptor antagonists, methoctramine (Met, selective M,
receptor antagonist, 10+7 M), AF--DXI16 (AF-DX, selective M , receptor antagonist, 10-'
M) and 4-DAMP (DAMP, selective M, receptor antagonist, 10-' M) on the ACh-induced
increase in membrane-associated RhoA in rat bronchial smooth muscle. A) Typical
photograph of bands for RhoA (Upper) and P-actin (Lower) in membrane fraction by
immunoblots. The bronchi were pretreated with muscarinic receptor antagonists for 10 min
before stimulation by ACh (10'3 M). Ten min after the ACh stimulation, the reaction was
stopped by liquid nitrogen, and tissues were homogenized to prepare cytosolic and
membrane fractions. Western blot was performed by using cytosolic and membrane
fractions both on RhoA and P-actin in the identical transferred membrane, and the ratios of
RhoA to the corresponding 6-actin band densities were calculated and summarized in B)
(membrane RhoA/total RhoA). Values are the means Å} S.E. from 4-5 experiments.
ACh-induced increase in membrane-associated RhoA was significantly inhibited by
pretreatment with 4-DAMP, but not with methoctramine and AF-DXI16. *pÅqO.05 and
*"* pÅqO.oo1 vs. None. ifpÅqO.05 vs. vehicle (ACh alone).
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Discussion
      In the airways, the existence of three muscarinic receptor subtypes (M,, M, and M,)
has been demonstrated by competition binding study.58) In their report, the central airway
(including trachea and extrapulmonary bronchi) contains both M, and M,
receptors (70 9o of the receptors are M ,, while the remaining 30 9o are M ,) and
the peripheral airway (including intrapulmonary bronchi, bronchioles and alveoli) contains
all the three receptors (more than 80 9o of the receptors are M ,). Thus, it can be expected
that 1arge amount of M , and remaining M , receptors exist in bronchial tissue of the rat.
However, the most important subtype that contributes to the ACh-induced contractile
response of the rat bronchial smooth muscle is not clear. So in this study, identification of
muscarinic receptor subtype of rat bronchial smooth muscle was performed by using
pharmacological analysis.
      In this study, the ACh-induced bronchial smooth muscle contraction could be
antagonized with high ad/finity by 4-DAMP and with Iow aff7inity by pirenzepine and
methoctramine. My findings of the rat study are in agreement with those of the studies in the
airway smooth muscle contractions of the guinea pig,60) cow,6i) dog,62) mouse63) and horse.64)
The reported affinities of pirenzepine, methoctramine and 4-DAMP for muscarinic receptors
are as follows; 7.8-8.5, 7.1-7.8 and 8.6-9.2 for M,,6.3-6.7, 7.8-8.3 and 7.8-8.4, for M, and
6.7-7.1, 6.3-6.9 and 8.9-9.1 for M,, respectively.65) Taking together, the pA, values obtained
in this study indicate that the most important muscarinic receptor mediating the ACh-induced
contractjon of rat bronchjal smooth muscle is of the M, type.
       Studies of Ca2' sensitization demonstrated G-protein-dependent augmentation of
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contractile activity at fixed Ca2' concentrations.20'66'69) The pathway is initiated by
receptor-mediated activation of a heterotrimeric G-protein coupled with activation of the
monomeric G-protein RhoA via dissociation of the Rho guanine nucleotide dissociation
inhibitor (RhoGDI). When activated by agonists acting on surface membrane receptors in
permeabilized smooth muscle, RhoA dissociates from its cytosolic complex with GDI and
translocates to surface membrane.`7'48) Activated RhoA is translocated to the plasma
membrane where it stimulates a specific Rho kinase.`7) In this study, the ACh-induced
increase in membrane-associated RhoA in rat bronchial smooth muscle was inhibited by
4-DAMP, suggesting that M3 receptor, but not M, receptor, has an important role in
ACh-induced RhoA activation. Lately, Murthy et al.70) demonstrated that ACh-induced
activation of Rho kinase and myosin phosphatase (MYPT) phosphorylation were inhibited
by pretreatment with 4-DAMP in rabbit intestine smooth muscle cell. Activation of
transfected human M, receptor induced cytoplasmic myosin reorganization by
Rho-dependent mechanism in Chinese hamster ovary (CHO-m3) cells.'i) This result might
be consistent with the current study, We previously reported the existence of ACh-induced
Ca2' sensitization in P-escin-permeabilized bronchial smooth muscle, which was inhibited
by a RhoA inhibitor, C3 exoenzyme22) and Y-27632.72) Moreover, distinct expression of
ROCK-I (p160 ROCK) and ROCK-II (Rho-kinase ct) was also demonstrated in airway
smooth muscle.72'73) Thus, the RhoA/ROCK pathway seems to be considered as a major
signaling pathway in upstream of ACh-induced Ca2' sensitization in rat bronchial smooth
muscle. Although the signal transduction between M, and RhoA is not solved currently,
further research is required about these mechanisms.
      In conclusion, the current findings clearly demonstrated that ACh induces
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contraction and an increase in membrane-associated RhoA protein
muscarinic M3 receptors in rat bronchial smooth muscle.
via activation of
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                          Chapter 4:
   A possible involvement of TNF-alpha in the
augmented bronchial smooth muscle contraction
Introduction
      The inflammation of asthmatic lungs is characterized by infiltration of eosinophils,
mast cells and lymphocytes to airway walls. Activation of these cells results in the release of
a plethora of inflammatory mediators that individually or in concert induce changes in the
airway wall geometry and produce the symptoms of the disease. On the other hand, there is
increasing evidence that tumor necrosis factor-alpha (TNF-alpha), one of the
proinflammatory cytokines released from these inflammatory cells, is directly linked to
airway inflammation and hyperresponsiveness observed in asthma.23) TNF-alpha is elevated
in the sputa and bronchoalveolar lavage fluid (BALF) of patients with bronchial asthma.2`'25)
In mouse25) and guinea pig27) models of lung inflammation, increased levels of TNF-alpha
have been detected in the BALF of sensitized animals following challenge with antigen. In
addition, in vivo pretreatment of rat and human airways with aerosolized TNF-alpha
produced an enhanced increase in airway resistance similar to that observed in asthma, when
challenged with endogenous agonists.28'29) Phamiacological evidence has also pointed
towards an important role of TNF-alpha in AHR. TNF-alpha receptor fusion protein, which
can potently block endogenous TNF-alpha, was effective in reducing both the enhanced
airway reactivity and inflammatory cells infiltration into the airways in sensitized guinea pigs
and Brown-Norway rats in vivo.30) Moreover, incubation with TNF-alpha of airway
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smooth muscle cells can produce an increase in agonist--stimulated intracellular Ca2'
release.33) These observations suggest that TNF-alpha may be one of the primary
components responsible for the bronchial smooth muscle hyperresponsiveness observed in
asthma. Indeed, it was demonstrated that TNF-alpha augmented muscarinic receptor
agonist-induced airway smooth muscle contractions in humans32) and mice.74)
       We have already demonstrated the occurrence of both in vivo and in vitro
hyperresponsiveness in rats that were actively sensitized and repeatedly challenged with
aerosolized antigen.6") We previously reported that the muscarinic receptor density of
bronchial tissues in AHR rat model with repeated antigen challenge was within normai
level.') Moreover, no significant difference in the ACh-induced increase in cytosolic Ca2'
concentration of the main bronchial smooth muscle was observed between the control and
AHR rats.22) These findings strongly suggest that the mechanisms responsible for the
augmented ACh-induced contraction of the main bronchial smooth muscle might exist in
post-muscarinic receptor signaling including an augmented Ca2' sensitization. In the
previous study, the level of RhoA, an important protein that mediates Ca2' sensitization2i)
and ACh-induced Ca2' sensitization in bronchial preparation of repeatedly antigen
challenged rats were significantly increased as compared with those of control rats. The
Ca2' sensitization was abolished by pretreatment with C3 toxin, Rho inhibitor. 22) It is
therefore possible that the increased RhoA seems to enhance the Ca2' sensitizing signal,
resulting in an augmentation of ACh-induced contractile response in a rat model of AHR.
       Mitogen-activated protein kinase (MAPKs), a family of serine/threonine kinases,
consist of at least three distinct members: exmacellular signal-regulated kinase (ERK, also
called p42/44 MAPK), p38 IVLAPK, and c-Jun NH,-terminal kinase (JNK).3`) MAPKs
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regulate a variety of cellular responses, including inflammation, cell cycle progression,
proliferation, differentiation and protein synthesis.35) Recently, p38 and p42/44 MAPKs
were reported to be activated by proinflammatory cytokines such as TNF-alpha.36)
However, whether MAPKs are involved in the TNF-alpha-induced airway
hyperresponsiveness is sti11 unclear. The effects of inhibitors of p38 maPK, MEK and
protein synthesis on the TNF-alpha augmented ACh-induced bronchial smooth muscle
contraction were therefore investigated. Fumhermore, the phosphorylation of p42/44 MAPK
and upregulation of RhoA protein by TNF-aipha, and the effect of MEK inhibitor on
TNF-alpha-induced upregulation of RhoA protein were elucidated by immunoblot analysis.
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Experiment 4-1: TNF-alpha-induced augmentation
of bronchial smooth muscle contraction
Materials and Methods
Animals
      Male Wistar rats weighing 170-190 g (6 weeks of age), purchased from Charles
River Japan, Inc., were housed under standard laboratory conditions as described in
Experiment 1-1.
Functional study
      The animals were killed by exsanguination from abdominal aorta under anesthesia
with chloral hydrate (400 mg/kg, i.p.). About 4 mm length of the left main bronchus was
isolated by the method as described in Experiment 1-1. The bronchial strips were incubated
with 1oo, 3oo or 1ooO nglmL TNF-alpha or its vehicle in the Krebs--Henseleit solution with
the following composition (mM); NaCl 118.0, KCI 4.7, CaCl, 2.5, MgSO, i.2, NaHCO,
25.0, KH,PO, 1.2 and glucose 10.0 (pH 7.4) at room temperature for 24 hr. The bronchial
rings were mounted on two L-shaped stainless prongs in a 5 mL organ bath. The organ bath
contained modified Krebs-Henseleit solution. The buffer solution was maintained at 37 OC
and oxygenated with 95 9o 02-5 9o C02. 0ne prong was connected to a force displacement
transducer (TB-612T, Nihon Kohden, Japan) for continuous recording of isometric tension.
The other prong was connected to a displacement device, allowing adjustment of the
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distance between the two paiallel prongs. The resting tension was set up by transducer
equipped with manipulator. In brief, just after seuing the tissue in an organ bath, a tension
(around 1.5 g) was loaded to the tissue. During an equilibration period in the organ bath, the
tissue was washed three to four times at 15 to 20 min intervals and equilibrated gradually to
a baseline tension of 1.0 g. In some case, further equilibration period was required for
tissue stabilization. Fifteen min after the last washing, higher concentrations of ACh were
successively added after attainment of a plateau response to the previous concentration.
After measurement of responsiveness to ACh, the bronchial smooth muscle was also
depolarized with isotonic high K ' solution prepared by iso-osmotic replacement of NaCl by
                    -6
                   .6
                      M atropine and 10
                       M indomethacin.KCI in the presence of 10
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Results
      Fig. 4-1 shows the effects of a 24 hr incubation with TNF-alpha on bronchial
smooth muscle responsiveness. As compared with vehicle-incubated control muscles, the
ACh responsiveness in TNF-alpha-treated groups was significantly augmented in a
TNF-alpha concentration-dependent manner (Fig. 4-IA): the Emax tension of the
TNF--alpha (3oo and 1ooO nglrnL)-treated groups (1.69 Å} O.09 g pÅqO.Ol and 1.76 Å} O.08
g, pÅqD.oo1, respectively) were significantly greater than that of the vehicle-incubated group
(1.16 Å} O.09 g). On the other hand, no significant difference in the response to isotonic high
K' (10, 30 and 60 mM) was observed among the groups (Fig. 4-IB).
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Fig. 4-1
Acetylcholine (ACh; A) and high K' (B) concentration-response curves for rat bronchial
ring following treatment with tumor necrosis factor-alpha (TNF-alpha; 1oo, 3oo and 1000
ng/mL) or its vehicle for 24 hr. Each point represents means with S.E. from 6 experiments.
In the TNF-alpha-treated group, the ACh responsiveness of the main bronchial smooth
muscles was significantiy (pÅqO.05, by ANOVA; 3oo ng /mL and pÅqO.Ol, by AVOVA;
10oo ng /mL) augmented as compared to the vehicle-treated group. *pÅqO.05, **pÅqO.Ol and
*** pÅqO.OOI (TNF-alpha, 1000 ng/mL) vs. vehicle. #pÅqO.05 and ##pÅqO.Ol (TNF-alpha,
3oo ng/mL) vs. vehicle.
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Experiment 4-2: Effects of MAPK inhibitors on
TNF-alpha-induced augmentation of bronchial
smooth muscle contraction
Materials and Methods
Animals
      Male Wistar rats weighing 170-190 g (6 weeks of age), purchased from Charles
lljver Japan, Inc., were housed under staRdard laboratory conditions as described in
Experiment 1-1.
Functional study
     The animals were ki11ed by exsanguination from abdominal aorta under anesthesia
with chloral hydrate (400 mglkg, i.p.). About 4 rnm length of the left main bronchus was
isolated by the method as described in Experiment 1-1. After treatment with 10 ptM UO126
(selective inhibitor of p42144 MAPK, MEK, activation), 30 ptM SB203580 (selective p38
MAPK inhibitor), 10 yM cyclohexirnide (inhibitor of protein synthesis) or O.1 9o dimethyl
sulfoxide (DMSO; their vehicle) for 1 hr, the bronchial strips were incubated with 300
nglmL TNF-alpha or its vehicle. The responsiveness to ACh was measured by the method
as described in Experiment 3-1.
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Results
      Fig. 4-2 shows the effect of 30 ptM SB203580, p38 MAPK inhibitor, on the
bronchial smooth muscle responsiveness after a 24 hr incubation with TNF-alpha (3oo
ng/mL). As compared with the TNF-alpha-treated control group, the augmented ACh
responsiveness by TNF-alpha was not significantly different from that in the
SB203580-treated groups. However, 10 geM UOI26, inhibitor of p42144 MAPK activation,
significantly inhibited the TNF-alpha-augmented ACh responsiveness. Moreover, the effect
of 10 ptM cycloheximide, inhibitor of protein synthesis, on the TNF-alpha-augmented
ACh-induced bronchial smooth muscle responsiveness was investigated. Cycloheximide
also significantly inhibited the TNF-alpha-augmented ACh responsiveness.
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Fig. 4-2
Effects of SB203580, UO126 and cycloheximide (CHX) on the augmentation of
ACh-induced contractile response evoked by TNF-alpha. The rat bronchial ring preparations
preincubated with SB203580 (30 ptM), UO126 (10 yM), CHX (10 psM) or its vehicle for l
hr were treated with TNF-alpha (300 ng/mL for 24 hr). After the 24 hr incubation period,
the bronchial smooth muscle responsiveness to ACh was measured isometrically. Each
point represents mean with S.E. from 4-8 experiments. The effect of TNF-alpha was
significantly inhibited by pretreatment with UO126 (pÅqO.05, by AVOVA) and CHX
(pÅqO.05, by AVOVA), but not with SB203580. *pÅqO.05, ""pÅqO.Ol, UO126 + TNF-alpha
vs. vehicle + TNFalpha. #pÅqO.05, #ifpÅqO.Ol, CHX + TNF-alpha vs. vehicle +
TNF-alpha.
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Experiment 4-3: TNF-alpha-induced upregulation of
RhoA in bronchiaR smooth muscle
Materials and Methods
Animals
      Male Wistar rats weighing 170-190 g (6 weeks of age), purchased from Charles
Kver Japan, Inc., were housed under standard laboratory conditions as described in
Experiment 1-1.
VVestern blot analysis
      To quantify the expression of RhoA proteins, Western blot was performed in the
homogenates of the main and intrapulmonary bronchi that were dissected from lung
parenchyma. Briefly, the samples were subjected to 15 9o SDS-polyacrylamide gel
electrophoresis. Proteins were then electrophoretically transferred to PVDF membranes.
After blocking, the membranes were then incubated with the primary antibodies. The
primary antibodies used rabbit anti-RhoA (1:2000 dilution; Santa Cruz Biotechnology, Inc)
or mouse anti-GAPDH (glyceraldehyde-3-phosphate dehydrogenase) (1:30oo dilution;
Chemicon). Then the membranes were incubated with horseradish peroxidase-conjugated
goat anti-rabbit immunoglobulin (Ig) G (1:5000 dilution; Amersham) and goat anti-mouse
IgG (1:5000 dilution; Amersham), detected by an ECL System. The ratio of corresponding
RhoA/GAPDH in each lane was calculated as an index of RhoA leyel. I used GAPDH as an
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internal control because this protein is also constitutively expressed in most tissues and is the
most widely accepted internal control in the molecular biology literature.
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Results
      In the present study, anti-RhoA antibody was used to detect RhoA protein of
TNF-alpha- and vehicle-treated bronchial preparations. Representative immunoblots for
RhoA and GAPDH from TNF-alpha-treated and its vehicle control preparations aie shown
in Fig. 4-3A. Immunoblotting with the antibody against RhoA showed a single 21 kD band,
indicating the existence of RhoA proteins in the rat bronchi. The ratios of corresponding
RhoA/GAPDH were calculated and represented in Fig. 4-3B. The relative expression of
RhoA protein in the TNF-alpha-treated bronchial preparation was significantiy increased as
compared with that in the vehicle control preparation (pÅqO.05).
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Fig. 4-3
(A) Typical immunoblots of RhoA (upper) and GAPDH (lower) in the TNF-alpha-treated
(300 nglmL, for 24 hr) or vehicle (Control)-treated bronchial preparations. (B) Relative
densities of RhoA to GAPDH (RhoAIGAPDH) in the TNF--alpha- or its vehicle-treated
bronchial preparations. Values are means with S.E. from 6 different animals. The
expression of RhoA was significantly increased in the TNF-alpha-treated bronchial
preparations as compared to that in the vehicle-treated ones (*pÅqO.05 vs. control).
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Experiment 4-4: Effect of p42/44 MAPK inhibitor,
UO126, on TNF-alpha-induced upregulation of
RhoA in bronchial smooth muscle
Materials and Methods
Animals
      Male Wistar rats weighing 170-190 g (6 weeks of age), purchased from Charles
Riyer Japan, Inc., were housed under standard Iaboratory conditions as described in
Experiment 1-1.
Western blot
      After treatment with 10 pM UO126 (selective inhibitor of p42144 MAPK, MEK,
activation) or O.1 9o dimethyl sulfoxide (DMSO; their vehicle) for 1 hr, the bronchial strips
were incubated with 300 ng!mL TNF-alpha or its vehicle for 24 hr and homogenated. The
samples were subjected to 15 9o SDS-polyacrylamide gel electrophoresis. Proteins were
then electrophoretically transferred to PVDF merribranes. After blocking, the membranes
were then incubated with the primary antibodies. As the primary antibodies, were used
rabbit anti-RhoA (1: 2000 dilution; Santa Cruz Biotechnology, Inc), mouse
anti-alpha-smooth muscle actin (1: 1000; Sigma), rabbit anti-myosin Iight chain (1: 1000;
Santa Cruz Biotechnology, Inc) or mouse anti-GAPDH (glyceraldehyde-3-phosphate
dehydrogenase) antibody (1: 3000 dilution; Chemicon). TheR the membranes were
incubated with horseradish peroxidase-conjugated goat anti-rabbit immunoglobulin (Ig) G
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(1: 50oo dilution; Amersham) and goat anti-mouse IgG (1: 5000 dilution; Amersham),
detected by an ECL system. The ratio of corresponding RhoA/GAPDH in each lane was
calculated as an index of RhoA, alpha-actin and MLC levels. We used GAPDH as an
intemal control because this protein is also constitutively expressed in most tissues and is
the most widely accepted as internal control in the molecular biology literature.
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Resuks
      In the present study, anti-RhoA antibody was used to detect RhoA protein in the
TNF-alpha- and vehicle-treated bronchial preparations. Representative immunoblots for
RhoA and GAPDH of the TNF-alpha-treated and control preparations aie shown in Fig.
"A. Immunoblouing with the antibody against RhoA showed a single 21 kD band,
indicating the existence of RhoA proteins in the iat bronchi. The ratios of corresponding
RhoA/GAPDH were calculated and represented in Fig. 4-4B. The expression of RhoA
protein in the TNF-alpha-treated bronchial preparation was significantly increased as
compared with that in the vehicle control one (pÅqO.05). Fig. 4-4 also shows the effects of
UO126 on the TNF-alpha-induced augmented expression of RhoA protein. UO126
significantly inhibited the RhoA expression induced by TNF--alpha (Fig. 4-4B). No
significant difference in the expression of ct-actin or MLC was observed between groups
(Fig. 4-5).
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Fig. 4-4
Eflfect of UO126 on the TNF-alpha-induced upregulation of RhoA protein. (A) Typical
immunoblots of RhoA (upper) and GAPDH (lower) in the control, vehicle + TNF-alpha
(300 nglmL, for 24 hr) and UO126 (10 ptM) + TNF-alpha treated bronchial preparations.
(B) Relative densities of RhoA to GAPDH (RhoAIGAPDH) in the bronchial preparation.
Values are means with S.E. from 4-6 different animals. The expression of RhoA was
significantly augmented in the TNF-alpha-treated bronchial preparation as compared to
control tissue (#pÅqO.05 vs. control). The augmented RhoA expression was inhibited in the
UO126 + TNF-alpha treated bronchial preparation as compared to the vehicle + TNF-alpha
treated one (*pÅqO.05 vs. TNF-alpha + vehicle).
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Fig. 4-5
(A) Typical immunoblots of myosin light chain (muC; upper), alpha-actin and GAPDH in
the TNF-alpha treated (3oo ngtML, for 24 hr) or vehicle (Control) treated bronchial smooth
muscle. (B) Relative densities of lvfl.C and alpha-actin to GAPDH in the TNF-alpha (closed
column) and vehicle (Contro1; open column) treated bronchial smooth muscles. Values are
means with S.E. from 4 different animals, respectively. No signifricant difference in the
expression of MLC and alpha-•actin was observed between groups.
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Experiment 4-5: TNF-alpha-induced augmentation
of ACh-induced phosphorylation of myosin light
chain in bronchial smooth muscle
Materials and Methods
Animals
      Male Wistar rats weighing 170-190 g (6 weeks of age), purchased from Charles
Itiver Japan, Inc., were housed under staAdard laboratory conditions as described in
Experiment 1-1,
Western blot analysis
      The bronchial preparations were incubated with 300 ng/mL TNF-alpha or its
vehicle in the Krebs-Henseleit solution at room temperature for 24 hr. The resulting
preparations were stimulated by ACh 10J3 M for 10 min. Then the samples were
homogenized with T-PER'M Tissue Protein Extraction Reagent (Pierce). After the samples
(20 ptg) were subjected to 15 9o SDS-polyacrylamide gel electrophoresis, Western blot was
performed. The membranes were incubated with the primary antibodies. As the primary
antibodies, were used goat anti-p-MLC (Thr 18/Ser19, 1:250 dilution; Santa Cruz
Biotechnology, Inc) or rabbit anti-myosin light chain (1: 1000; Santa Cruz Biotechnology,
Inc). Then the membranes were incubated with horseradish peroxidase-conjugated donkey
anti-goat immunoglobulin (Ig) G (1: 5ooO dilution; Santa Cruz Biotechnology, Inc) and goat
anti-rabbit immunoglobulin (Ig) G (1: 5000 dilution; Amersham), detected by an ECL
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system. The ratio of corresponding p-MLC/MLC was calculated as an index of p-MLC.
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Results
      Fig. 4-6 shows the effect of TNFalpha pretreatment on the ACh-induced
phosphorylation of MLC in rat bronchial preparations. By performing Western blot, MLC
phosphorylation was represented as a distinct single band in a manner analogous to previous
report. 27) Treatment with ACh induced a significant increase in MLC phosphorylation in
control preparations (no TNF-alpha), that is ACh-induced MLC phosphorylation. The
ACh-induced MLC phosphorylation was significantly augmented by TNFalpha
pretreatment. However, no significant difference in the phosphorylation of MLC of
basement was observed between groups with and without TNF-alpha.
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Fig. 4-6
(A) Typical immunoblots of acetylcholine (ACh; 10 -3 M)-induced phospholylated myosin
light chain (p-MLC; upper) and myosin light chain (MLC) in the TNF-alpha treated (300
nglmL, for 24 hr) or vehicle (Control) treated bronchial smooth muscle. (B) Relative
densities of p-MLC to MLC in the TNF-alpha and vehicle treated bronchial smooth muscles.
Values are means with S.E. from 4 different animals, respectively. MLC was significantly
phosphorylated by ACh treatment. In the pretreatment with TNF-alpha group, ACh-induced
phosphorylation was significantly augmented as compared to the control (vehicle) + ACh
("p,O.05 vs. Normal + ACh).
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Discussion
      In the present study, treatment of rat bronchial smooth muscles with TNF-alpha
(300 and 1000 ng/mL for 24 hr) significantly shifted upward the concentration-response
curve to ACh, but not to high K",as compared to that of control tissues. Thus, 300 ng/mL
TNF-alpha was used in most experiments. The augmented ACh responsiveness by
TNF-alpha was completely blocked by pretreatment with UO126 or cycloheximide, but not
with SB203580. To study whether TNF-alpha activates p42/44 MAPK in bronchial
preparation, phosphorylation of p42/44 MAPK was determined by immunoblotting.
Thereby, TNF-alpha induced a p42/44 MAPK phosphorylation in bronchial tissue. When
the expression of RhoA protein was quantified, TNF-alpha significantly increased the
expression of RhoA protein in the bronchus. UO126 inhibited the expression of RhoA
enhanced by TNF--alpha treatment in bronchus.
      TNF-alpha has reportedly been implicated in the pathophysiology of
proinflammatory disorders including bronchial asthma. Regarding bronchial asthma,
elevated levels of TNF-alpha have been detected in the BALF from asthmatic patients.
Exposure of human airway smooth muscle cells to TNF-alpha for 24 hr potentiates the
increase in cytosolic free calcium induced by contractile agonists such as carbachol and
bradykinin.25'3'År However, in the present study, TNF-aipha potentiated the ACh-, but not
high K'-, induced contraction of rat bronchial smooth muscle. Accordingly, TNF-alpha may
increase bronchial smooth muscle contractilities through agonist receptor such as muscarinic
receptor, but not those through Ca2' channel like voltage-dependent Ca2' channel (VDc).
      The authors previously demonstrated that the increased expression of RhoA protein
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by allergic stimulation seems to enhance the Ca2' sensitizing signal, resulting in an
augmentation of ACh-induced contractile response in the antigen-challenged AHR rats.22)
We presently confirmed that TNF-alpha treatment augments the ACh-induced bronchial
smooth muscle contraction; ACh has been reported as one of the activators of RhoA in
bronchial smooth muscle.59) I now demonstrated that TNF-alpha augmented the expression
of RhoA protein in bronchial preparation. Thus, TNF-alpha produced by allergic stimulation
might increase the agonist-induced Ca2' sensitizing signal via enhanced expression of RhoA
proteln.
       The mechanisms underlying the TNFalpha-induced increase in bronchial smooth
muscle contractilities have not been fu11y elucidated so far. TNF-alpha initiates its pleiotropic
action by binding to two types of receptor designated as p55 (TNFRI) and p75 (TNFR2)
according to their apparent molecular mass. These receptors aie coexpressed on the surface
of mast cells.'5) Although both TNFRI and TNFR2 were found to be coexpressed on
airway smooth muscle ce11s,33'7`) the majority of TNF-alpha effects on airway smooth
muscle are mediated by TNFRI.'`År TNFRI was shown to regulate the TNF-alpha-induced
expression of adhesion molecules.2') Howeyer, the receptor type implicated in the
TNF-alpha-induced increase in bronchial smooth muscle contractilities and in the expression
of RhoA protein has not been identified.
       A number of studies have demonstrated the involvement of MAPKs in modulating
airway smooth muscle cell proliferation. However, it is unclear whether MAPKs participate
in the agonist-induced bronchial smooth muscle contractilities augmented by TNF-alpha.
Although the transcription factor(s) involved in RhoA expression is not known now, it has
been suggested that TNF-alpha modulates gene transcription via activation of MAPK, that is
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phosphorylation of MAPK.'7) It has also been reported that the phosphorylation of MAPK
occurs immediately after TNF-alpha stimulation.'8) So in the present study, the
phosphorylation level of MAPK was measured 10 to 20 min after the TNF-alpha stimulation
to determine whether MAPK is also activated by TNF-alpha in rat bronchial smooth muscle.
Although Amrani et al.7') have demonstrated that TNF-alpha activated p38 MAPK in airvvay
smooth muscle cells, SB203580 did not prevent the TNF-alpha-induced potentiation of the
ACh-induced contraction of rat bronchial smooth muscle was showed. However, the
present study has demonstrated that TNF-alpha activates p42/4Zl MAPK in rat bronchus and
that an inhibition of p42/44 MAPK activation by UO126 completely blocked the
TNF-alpha-induced potentiation of the ACh-induced contraction of rat bronchial smooth
muscle. Funherrnore, the augmented ACh-induced bronchial smooth muscle contraction by
TNF-alpha was aboiished by cycloheximide, inhibitor of protein synthesis. These findings
suggest that the augmentation of the ACh-induced bronchial smooth muscle contraction by
TNF-alpha may involve protein synthesis process including RhoA protein through p42/44
IVL4LPK pathway.
       Although the transcription factor(s) involved in RhoA expression is not known
now, it has been suggested that TNF-alpha modulates gene transcription via activation of
MAPK, that is phosphorylation of MAPK.7') It has also been reported that the
phosphorylation of MAPK occurs immediately after TNF-alpha stimulation.78) So in the
present study, the phosphorylation level of MAPK was measured 10 to 20 min after the
TNF-alpha stimulation to determine whether MAPK is also activated in rat bronchial smooth
muscle.
       In the present study, TNF-alpha augmented the ACh-induced maximal contraction
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with an increased expression of RhoA in bronchial smooth muscle, whereas no significant
increase in the contractile proteins was observed (Fig. 4-5). The result might consist with
our previous study that the maximal contraction induced by ACh was augmented
concurrently with an overexpression of RhoA protein in bronchial smooth muscles of
antigen-induced AHR rats in Chapter Z whereas no change in high K'
depolarization-induced contraction was observed in Chapter 1.79) By using the rat model of
AHR, the present study suggest that the maximal response of ACh-induced Ca 2'
sensitization was significantly augmented and was completely abolished in the presence of a
RhoA inhibitor, C3 exoenzyme.22) Indeed, in the present study, I demonstrated that
ACh-induced phosphorylation of MLC was augmented by pretreatment with TNF-alpha.
Thus TNF-alpha may augment agonist-induced maximum contraction. Moreover, the
increased expression of RhoA protein might affect the maximal contraction induced by
constnctor agomsts.
       The delayed increase in the protein expression induced by TNF-alpha may be
initiated by the early phosphorylation of MAPK.'7'78'80) For instance, chen et al.80) reported
that the TNF-induced increase in monocyte chemoattractant protein type 1 (MCP-1), which
was observed ev24 hr after TNF-alpha treatment, is mediated via the activation of MAPK and
transcriptional factors such as AP-1 and NF-KB in vascular smooth muscle cell. They also
demonstrated that the TNF-alpha-induced phosphorylation of MAPK occurs within 30 min.
Both the MAPK phosphorylation and MCP-1 overexpression induced by TNF-alpha were
abolished by PD98059, an inhibitor of p42/44 MAPK activator. So in the present study, the
MAPK phosphorylation was measured 10 and 20 min after treatment with TNF-alpha to
identify an initial event for the TNF-alpha induced increase in RhoA expression.
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      In conclusion, it is suggested that TNF-alpha might be one of the important
mediators that are involved in the pathogenesis of the augmented bronchial smooth muscle
contiactility at antigen-induced AHR. The augmentation of ACh-induced contractile
response evoked by TNF-alpha is proposed to be mediated by synthesis of protein(s) such
as RhoA through an activation of p42144 MAPK, but not of p38 MAPK, in rat bronchial
smooth muscle.
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             Conclusion
The present studies lead to the following conclusions:
1. ACh-induced conmactile response of bronchial smooth muscle was significantly
   augmented in the AHR rats, although the increment in ECa2'], was within the control
   levels. These findings strongly suggest an augmentation of ACh-induced myofilaments
   Ca2' sensitization in bronchial smooth muscles from the AHR rats.
2. ACh induced a RhoA translocation to plasma membrane - i.e. an activation of RhoA -
   in rat freshly isolated bronchial smooth muscle cells and tissues. The level of
   ACh-induced RhoA translocation was markedly increased in AHR as compared with
   that in the control group. These findings suggest that the augmented activation of RhoA
   observed in the hyperresponsive bronchial smooth muscle might be responsible for the
   enhanced ACh-induced Ca 2' sensitization of bronchial smooth muscle contraction at the
   AHR in rats.
3. The current findings clearly demonstrated that the most important muscarinic receptor
   mediating the ACh-induced contraction and translocation of RhoA protein of rat
   bronchial smooth muscle is of the M, subtype.
4. TNF-alpha might be one of the important mediators that are involved in the
   pathogenesis of the augmented bronchial smooth muscle contractility at antigen--induced
   AHR and that the augmentation of ACh-induced contractile response evoked by
   TNF-alpha is mediated by synthesis of protein(s) such as RhoA through an activation of
   p42/4Zl MAPK, but not of p38 MAPK, in rat bronchial smooth muscle.
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